Phenotypic Variation and Carbapenem Resistance Potential in OXA-499-Producing .

is increasingly recognized as a clinically important species. Here, we identified a carbapenem-non-resistant clinical isolate, A1254, harboring , , and . The genetic environment in A1254 was identical to that of another OXA-499-producing, but carbapenem-resistant, isolate, YMC2010/8/T346, indicating the existence of phenotypic variation among OXA-499-producing strains. Under imipenem-selective pressure, the A1254 isolate developed resistance to carbapenems in 60 generations. Two carbapenem-resistant mutants (CAB009 and CAB010) with mutations in the promoter region were isolated from two independently evolved populations (CAB001 and CAB004). The CAB009 mutant, with a mutation at position -14 (A to G), exhibited a four-fold higher carbapenem minimum inhibitory concentration (MIC) and a 4.53 ± 0.19 log fold change higher expression level of than the ancestor strain, A1254. The other mutant, CAB010, with a mutation at position -42 (G to A), showed a two-fold higher carbapenem MIC and a 1.65 ± 0.25 log fold change higher expression level than the ancestor strain. The gene and its promoter region were amplified from the wild-type strain and two mutant isolates and then individually cloned into the pYMAb2-Hyg vector and expressed in ATCC 17978, LMG 1035, and A1254. All the transformed strains were resistant to carbapenem, irrespective of whether they harbored the initial or an evolved promoter sequence, and transformed strains expressing the promoter from the most resistant mutant, CAB009, showed the highest carbapenem MICs, with values of 32-64 μg/ml for imipenem and 128 μg/ml for meropenem. RNA sequencing was performed to confirm the contribution of to the development of carbapenem resistance. Although the CAB009 and CAB010 transcriptional patterns were different, was the only differentially expressed gene shared by the two mutants. Our results indicate that carbapenem-non-resistant spp. strains carrying genes have the potential to develop carbapenem resistance and need to be further investigated and monitored to prevent treatment failure due to the development of resistance.